Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immunomedics, Inc. (NASDAQ: IMMU).

Full DD Report for IMMU

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMMU)

Premarket Gainers as of 9:05 am (5/17/2018)
BLNK +16% . More news on: Blink Charging Co., Minerva Neurosciences, Loxo Oncology, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 09:19
Immunomedics' lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarket
Immunomedics (NASDAQ: IMMU ) is up  8%  premarket on light volume on the heels of its release of data on antibody-drug conjugate IMMU-132 (sacituzumab govitecan) in heavily pretreated patients with ER+/HER2- metastatic breast cancer. The results will be presented at ASCO in Chica...
Source: SeekingAlpha
Date: May, 17 2018 09:05
Today's Research Reports on Trending Tickers: Immunomedics and Rite Aid
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / U.S. markets closed up on Wednesday, as investors appear to shrug off fears of increasing interest rate and bond yields. The Dow Jones Industrial Average gained 0.25 percent to close at 24,768.93, while the S&P 500 Index increased 0.41 percent ...
Source: ACCESSWIRE IA
Date: May, 17 2018 08:00
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Company to Host Investor E...
Source: GlobeNewswire
Date: May, 16 2018 17:01
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
Immunomedics, Inc. (IMMU) CEO Michael Pehl on Q3 2018 Results - Earnings Call Transcript
Immunomedics, Inc. (IMMU) Q3 2018 Earnings Conference Call May 9, 2018 05:00 p.m. ET Executives Michael Pehl - President, Chief Executive Officer Robert Iannone - Head of Research & Development, Chief Medical Officer Mike Garone - Vice President Finance, Chief Financial Offic...
Source: SeekingAlpha
Date: May, 09 2018 21:54
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
Biologics License Application (BLA) Remains on Track to be Submitted by the End of May 2018 Leadership Team Expanded with Appointment of Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer Abstract of Sacituzumab Govitecan in Treatment-Refractive, Hor...
Source: GlobeNewswire
Date: May, 09 2018 16:00
Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Entergy Corporation (NYSE:ETR), Schneider National, Inc. (NYSE:SNDR), C.H....
Source: GlobeNewswire
Date: May, 09 2018 07:30
Small Caps: The Bright Spot In A Challenging Stock Market
Market Pulse The stock market is unpredictable and volatile and investors are being administered a high dosage of these nerve-wracking reminders during 2018. The high volatility this year appears to feel like a punishment meted out for the low-volatility indulgences of a mellow 2017 when sto...
Source: SeekingAlpha
Date: May, 07 2018 15:21
Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018
MORRIS PLAINS, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Wednesday, May 9, 2018 at 5:00 p.m. Eastern Time to discuss third quarter fiscal 20...
Source: GlobeNewswire
Date: May, 02 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1522.4321.62522.8121.451,466,078
2018-08-1422.7522.49523.13922.231,187,894
2018-08-1323.6422.7923.9822.63843,903
2018-08-1023.1523.6523.9223.15517,213
2018-08-0923.4823.3423.8423.34691,219

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1484,898279,24030.4032Cover
2018-08-1366,742203,85132.7406Cover
2018-08-1028,08088,71931.6505Cover
2018-08-0936,736256,50014.3220Cover
2018-08-0886,320287,31630.0436Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMU.


About Immunomedics, Inc. (NASDAQ: IMMU)

Logo for Immunomedics, Inc. (NASDAQ: IMMU)

Not available

 

Contact Information

 

 

Current Management

  • Cynthia L. Sullivan / President, CEO
  • Shailesh R. Asher / Acting CFO

Current Share Structure

  • Market Cap: $3,148,230,032 - 05/11/2018
  • Issue and Outstanding: 165,783,572 - 02/08/2018

 


Recent Filings from (NASDAQ: IMMU)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 02 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: IMMU)

Daily Technical Chart for (NASDAQ: IMMU)


Stay tuned for daily updates and more on (NASDAQ: IMMU)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMMU)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMU is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IMMU and does not buy, sell, or trade any shares of IMMU. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/